3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase EARLY_PHASE1
1
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma Locally Advanced
1
Neoplasm Metastasis
1
Melanoma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
HIV Seropositivity
1
Gynecological Cancers
1
Colorectal Neoplasms
1
Colorectal Liver Metastases
1
Carcinoma, Hepatocellular
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
Electroporation
×
Clear all
NCT04835402
2022-03-09
EPIC-1
Aalborg University Hospital
Phase 2
Unknown
8 enrolled